Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications.

Paini A, Leonard JA, Kliment T, Tan YM, Worth A.

Regul Toxicol Pharmacol. 2017 Nov;90:104-115. doi: 10.1016/j.yrtph.2017.08.019. Epub 2017 Sep 1.

2.

Integrating in vitro data and physiologically based kinetic (PBK) modelling to assess the in vivo potential developmental toxicity of a series of phenols.

Strikwold M, Spenkelink B, de Haan LHJ, Woutersen RA, Punt A, Rietjens IMCM.

Arch Toxicol. 2017 May;91(5):2119-2133. doi: 10.1007/s00204-016-1881-x. Epub 2016 Nov 4.

3.

Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay.

Colaianna M, Ilmjärv S, Peterson H, Kern I, Julien S, Baquié M, Pallocca G, Bosgra S, Sachinidis A, Hengstler JG, Leist M, Krause KH.

Arch Toxicol. 2017 Jan;91(1):365-391. doi: 10.1007/s00204-016-1690-2. Epub 2016 Mar 25.

4.

Laboratory Rodent Diets Contain Toxic Levels of Environmental Contaminants: Implications for Regulatory Tests.

Mesnage R, Defarge N, Rocque LM, Spiroux de Vendômois J, Séralini GE.

PLoS One. 2015 Jul 2;10(7):e0128429. doi: 10.1371/journal.pone.0128429. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0135542.

5.

Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach.

Krug AK, Kolde R, Gaspar JA, Rempel E, Balmer NV, Meganathan K, Vojnits K, Baquié M, Waldmann T, Ensenat-Waser R, Jagtap S, Evans RM, Julien S, Peterson H, Zagoura D, Kadereit S, Gerhard D, Sotiriadou I, Heke M, Natarajan K, Henry M, Winkler J, Marchan R, Stoppini L, Bosgra S, Westerhout J, Verwei M, Vilo J, Kortenkamp A, Hescheler J, Hothorn L, Bremer S, van Thriel C, Krause KH, Hengstler JG, Rahnenführer J, Leist M, Sachinidis A.

Arch Toxicol. 2013 Jan;87(1):123-43. doi: 10.1007/s00204-012-0967-3. Epub 2012 Nov 21.

6.

Alternatives to animal testing: current status and future perspectives.

Liebsch M, Grune B, Seiler A, Butzke D, Oelgeschläger M, Pirow R, Adler S, Riebeling C, Luch A.

Arch Toxicol. 2011 Aug;85(8):841-58. doi: 10.1007/s00204-011-0718-x.

7.

The embryonic stem cell test as tool to assess structure-dependent teratogenicity: the case of valproic acid.

Riebeling C, Pirow R, Becker K, Buesen R, Eikel D, Kaltenhäuser J, Meyer F, Nau H, Slawik B, Visan A, Volland J, Spielmann H, Luch A, Seiler A.

Toxicol Sci. 2011 Apr;120(2):360-70. doi: 10.1093/toxsci/kfr001. Epub 2011 Jan 11.

8.

Present state and future perspectives of using pluripotent stem cells in toxicology research.

Wobus AM, Löser P.

Arch Toxicol. 2011 Feb;85(2):79-117. doi: 10.1007/s00204-010-0641-6. Epub 2011 Jan 12. Review.

9.

The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative.

Blaauboer BJ, Andersen ME.

Arch Toxicol. 2007 May;81(5):385-7. Epub 2007 Jan 30. No abstract available.

Supplemental Content

Support Center